Elevated pericoronary fat attenuation index was not significantly associated with all-cause mortality in the overall chronic kidney disease cohort, but predicted greater mortality in the end-stage renal disease subgroup (HR 2.26).
Cohort (n=209)
No
Does a high pericoronary fat attenuation index (FAI) on CTA predict all-cause mortality in patients with chronic kidney disease and end-stage renal disease?
Elevated pericoronary fat attenuation index at the LAD on CTA is a significant predictor of long-term all-cause mortality in patients with end-stage renal disease.
Hazard Ratio: 2.08 (95% CI 0.94–3.51)
Absolute Event Rate: 146.8% vs 71.2%
BACKGROUND: An increased pericoronary fat attenuation index (FAI) on computed tomography angiography (CTA) is associated with increased all-cause and cardiac mortality in the general population. However, the ability of pericoronary FAI to predict long-term outcomes in chronic kidney disease (CKD) patients is unknown. METHODS: In this single-center retrospective longitudinal cohort study, we assessed the utility of CTA-based pericoronary FAI measurement to predict mortality of CKD patients, including those with end-stage renal disease (ESRD). Mapping and analysis of pericoronary FAI involved three major proximal coronary arteries. The prognostic value of pericoronary FAI for long-term mortality was assessed with multivariable Cox regression models. RESULTS: Among 268 CKD participants who underwent coronary CTA, 209 participants with left anterior descending artery (LAD) FAI measurements were included. The pericoronary FAI measured at the LAD was not significantly associated with adjusted risk of allcause mortality (hazard ratio HR, 2.08; 95% confidence interval CI, 0.94-3.51) in any CKD group. However, ESRD patients with elevated pericoronary FAI values had a greater adjusted risk of all-cause mortality compared with the low-FAI group (HR, 2.26; 95% CI, 1.11-4.61). CONCLUSION: The pericoronary FAI measured at the LAD predicted long-term mortality in patients with ESRD, which could provide an opportunity for early primary intervention in ESRD patients.
Cho et al. (Tue,) conducted a cohort in Chronic kidney disease (n=209). Elevated pericoronary fat attenuation index (FAI) vs. Low pericoronary FAI was evaluated on All-cause mortality (HR 2.08, 95% CI 0.94-3.51). Elevated pericoronary fat attenuation index was not significantly associated with all-cause mortality in the overall chronic kidney disease cohort, but predicted greater mortality in the end-stage renal disease subgroup (HR 2.26).